NCT02503722View on ClinicalTrials.gov

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 23, 2017

Primary Completion Date

June 5, 2026

Study Completion Date

June 5, 2026

Conditions
Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage III Lung Non-Small Cell Cancer AJCC v7Stage IIIA Lung Non-Small Cell Cancer AJCC v7Stage IIIB Lung Non-Small Cell Cancer AJCC v7Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Osimertinib

Given PO

OTHER

Pharmacological Study

Correlative studies

DRUG

Sapanisertib

Given PO

Trial Locations (5)

33612

Moffitt Cancer Center, Tampa

06510

Smilow Cancer Center/Yale-New Haven Hospital, New Haven

06520

Yale University, New Haven

V5Z 4E6

BCCA-Vancouver Cancer Centre, Vancouver

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH